Companies: 10,795·Total market cap: $144.5T
Beam Therapeutics Inc.

Beam Therapeutics Inc.

BEAMNASDAQHealthcare● Active
$29.40
$-3.44(-10.48%)
Market Cap$3.0B
P/E Ratio
52W High$36.44
52W Low$15.6

Beam Therapeutics Inc. (BEAM) Stock Forecast & Analyst Price Target

Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.

beam · stock forecast · 27 analysts (3M) · FMP · updated Jun 8, 2026

Analyst Rating & Consensus

Based on 27 Wall Street analysts in the past 3 months

SellBuy

Buy

27 analysts

consensus

Rating Breakdown

Strong Buy
0
Buy
18
Hold
8
Sell
1
Strong Sell
0
Total: 27 · Buy rate: 66.7%

12-Month Price Target

High

$80.00

Consensus

$48.00

+63.3% upside

Low

$26.00

Median: $40 · Last Close: $29.40

The Beam Therapeutics Inc. (BEAM) analyst consensus is Buy, based on ratings from 27 Wall Street analysts over the past 3 months. The average 12-month BEAM price target is $48.00, representing +63.3% upside from the current price of $29.40.

12-Month Price Target Forecast

Historical closing prices + analyst 12-month price target forecast cone

Historical priceConsensus $48 (63.3%)

Consensus Target

$48.00

63.3% upside

High Target

$80

172.1%

Low Target

$26

-11.6%

Current Price

$29.40

as of today

Based on analyst price targets, the BEAM stock price prediction for the next 12 months ranges from $26 to $80. The consensus BEAM price forecast of $48.00 implies 63.3% upside from the current price of $29.40.

Short-Term Price Prediction

Algorithmically generated · Updated daily

DatePredicted PriceChange
2026-06-09$29.620.74%

1-day model range: $29.33–$29.9. Peak: $29.9 (+0.74%).

Long-Term Stock Price Prediction

Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031

YearAvg PriceChange
2027$19-34.0%
2028$15-47.4%
2029$14-53.8%
2030$13-57.2%
2031-59.1%
Confidence:Medium

Stock Forecast Based on Technical Analysis

14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency

Market Sentiment

NEUTRAL

Based on 14 technical indicators

50%7%43%
7Buy
1Neutral
6Sell
RSI (14)53.8Neutral
MACDBULLISH

Refreshes daily from EOD close

Moving Averages · BEAM · Jun 8, 2026

Simple Moving Average (SMA)
MA 5$30.38SELL
MA 10$30.79SELL
MA 20$30.04SELL
MA 50$28.92BUY
MA 100$28.46BUY
MA 200$26.35BUY
Current $BEAM · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$30.53SELL
EMA 10$30.44SELL
EMA 20$30.15SELL
EMA 50$29.30BUY
EMA 100$28.28BUY
EMA 200$26.77BUY
Current $BEAM · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

Latest Analyst Ratings & Upgrades

Filter:
Bernstein2026-05-13
Maintains
OutperformOutperform
Citigroup2026-03-26
Maintains
BuyBuy
Wedbush2026-02-25
Maintains
OutperformOutperform
RBC Capital2026-02-25
Maintains
Sector PerformSector Perform
Bernstein2026-01-21
Maintains
OutperformOutperform
HC Wainwright & Co.2025-10-10
Maintains
BuyBuy
JP Morgan2025-10-09
Maintains
OverweightOverweight
HC Wainwright & Co.2025-09-15
Maintains
BuyBuy
Barclays2025-08-06
Maintains
Equal WeightEqual Weight
Barclays2025-05-07
Maintains
Equal WeightEqual Weight

Wall Street analysts have recently issued updated ratings on Beam Therapeutics Inc. (BEAM) stock. Of the recent 94 rating actions, 10 were upgrades and 8 were downgrades. 27 analysts currently cover BEAM.

Analyst Recommendation Trends

Buy ratings11
Hold ratings00
Sell ratings00

BEAM analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.

Financial Forecast: EPS & Revenue Estimates

Revenue This Year

$71M

↓ 47.6% YoY

Revenue Next Year

$79M

↑ 10.9% YoY

EPS This Year

$-4.42

EPS Next Year

$-4.59

↑ 3.8% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast BEAM EPS of $-4.42 for the current fiscal year, based on estimates from 12 analysts. The BEAM revenue forecast is $71M for the current year. These are analyst consensus estimates via FMP / S&P Global.

About Forecast & Price Prediction

The BEAM stock forecast is supported by two independent data sources: analyst consensus ratings from 27 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus BEAM price target is $48.00 (+63.3% upside), with an analyst consensus of Buy.

The BEAM short-term stock prediction for tomorrow is $29.62 (+0.74%). The BEAM stock price prediction for 2027 estimates an average of $19. The BEAM stock prediction for 2030 projects a range of $11–$14.

Beam Therapeutics Inc. trades on NASDAQ under the ticker BEAM. The BEAM stock outlook for 2027 is broadly positive, supported by a Buy consensus among 67% of covering analysts.

FAQ answers synthesize analyst targets, estimates, and on-page model outputs where shown.

Frequently asked questions

BEAM forecast · 8 questions

According to 27 Wall Street analysts, the average 12-month BEAM price target is $48.00, with a high forecast of $80.00 and a low of $26.00. The median price target is shown in the chart above when available. This implies +63.3% potential upside from the current price of $29.40.

BEAM price targetWhat is BEAM price targetBEAM analyst price targetBEAM 12-month target

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.